**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE/ZIDOVUDINE DISPERSIBLE TABLETS 30 mg/60 mg | | REF. NO: NDQD201508108 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each dispersible tablet contains: Lamivudine USP 30 mg, Zidovudine USP 60 mg. | |
| **BATCH NO.:** 3029718 | **PRESENTATION:** | Off white coloured, circular shaped, biconvex faced, single scored tablets and embossed with 'LZ' and '1' on either side of the scored face and 'M' on un-scored face, packed in a white plastic multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Aug. 2014 | **MANUFACTURER:** | MYLAN Laboratories Ltd. | |
| **EXP. DATE:** Jul. 2016 | **ADDRESS:** | H-12 & H-13, MIDC, Waluj, Aurangabad - 431136, Maharashtra, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 2.8 and 3.7 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Lamivudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 99.3% (RSD = 7.8%; n = 6) | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 98.4% (RSD = 2.1%; n = 6) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 95.3% (RSD = 0.9%; n = 9) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 97.6% (RSD = 0.3%; n = 9) | **COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. E. MUTUA |  | DATE:01-10-2015 |
| REVIEWER: | DR. G. WANG'ANG'A |  | DATE:14-10-2015 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-04-2015 |